Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Dense CMF in Early Stage Breast Cancer for Patients >= 70
NCT07768436Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2026
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide, methotrexate and fluorouracil in breast cancer (2 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of participants who have completed all four cycles of CMF at 6 months. Started Aug 2026; status: recruiting.
02
Drugs
cyclophosphamidemethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07768436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768436.